First new drug in years reduces recurrence in high risk HR+ early breast cancer
(European Society for Medical Oncology) Lugano, Switzerland, 20 September 2020 - Adding abemaciclib to hormonal therapy reduces the risk of cancer recurrence by 25% in patients with high-risk early hormone receptor positive (HR+) human epidermal growth factor receptor 2 negative (HER2-) breast cancer, according to results from a study at ESMO 2020.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news
More News: Breast Cancer | Cancer | Cancer & Oncology | HER2 | Hormonal Therapy | Hormones | International Medicine & Public Health | Study | Switzerland Health